Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders.
📄 Abstract
Depressive disorder represents a multifaceted and intricate condition characterized by disturbances in monoaminergic signaling, neurotrophic support mechanisms, and the regulation of inflammatory processes. An increasing body of evidence indicates that natural bioactive compounds may provide adjunctive therapeutic advantages with a reduced incidence of adverse effects in comparison to traditional antidepressants. This review investigates the antidepressant efficacy of
Confidence:
0.26
· 4 полей извлечено
Идентификация (6 полей)
Target
—
0.00
Alt. target
—
0.00
Protein family
—
0.00
Functional class
—
0.00
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
In vitro studies to investigate the potential neuroprotective and neurotransmitter modulation effects of a standardized Ginkgo biloba extract associated with phosphatidylserine.
0.90
In vivo
Rhodomyrtus tomentosa fruit alleviates hippocampal neuroinflammation and apoptosis and rescues neurogenesis to ameliorate depressive-like behaviors in CUMS-challenged mice.
0.90
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
CUMS-challenged mice
0.90
Diet/model
Rhodomyrtus tomentosa fruit
0.90